Clinical Trial NCT05744921
Trial
Regeneron – 2050 2021-004931-10 (NCT05744921)
Clinical trial ID
NCT05744921
Drug name
Pozelimab and Cemdisiran
Company:
Regeneron
Drug trade name
---
Clinicaltrials.gov
Learn more
Phase of study
3
Current status
Recruiting
Start
03/2023
Substance
Monoclonal antibody and RNAi
Research question
Safety, efficacy and tolerability of combination therapy
Delivery method of drug
s.c.
Frequency
Every four weeks
Clinical trial locations
Korea Canada Hungary India Italy Japan Malaysia Philippines Poland Romania Singapore Spain Taiwan Thailand Turkey